Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Riggs

Emergency Medicine Lafayette, IN Medical Doctor

NPI 1578508404 CMS profile 297647

1321 Unity Pl, Suite B, Lafayette, IN 47905

Open in the dashboard

General payments

$2,733

137 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Riggs of Lafayette, IN is reported in the CMS Open Payments database as having received $2,733 across 137 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,340 44
2024 General $410 16
2023 General $45 2
2022 General $233 18
2021 General $260 20
2020 General $208 20
2019 General $236 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Riggs
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Elizabeth Riggs were reported at $1,340. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Elizabeth Riggs Emergency Medicine median Middle half National median
2019 $236 $51 $18–$128 $163
2020 $208 $29 $16–$99 $114
2021 $260 $40 $18–$124 $132
2022 $233 $49 $20–$134 $149
2023 $45 $51 $22–$142 $160
2024 $410 $52 $22–$150 $164
2025 $1,340 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,750 60 payments
  2. Genentech USA, Inc. $356 31 payments
  3. AbbVie, Inc. $268 20 payments
  4. Biohaven Pharmaceuticals, Inc. $137 11 payments
  5. Lupin Inc. $55 3 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $45 3 payments
  7. Seqirus USA Inc $34 2 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $24 2 payments
  9. Roche Diagnostics Corporation $21 2 payments
  10. Kowa Pharmaceuticals America, Inc. $17 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,733 137 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $1,410 52 payments
  2. BREZTRI $635 9 payments
  3. Xofluza $356 31 payments
  4. NURTEC ODT $181 14 payments
  5. UBRELVY $175 13 payments
  6. QULIPTA $93 7 payments
  7. Fluad Quadrivalent $34 2 payments
  8. FLUCELVAX QUADRIVALENT $34 2 payments
  9. SOLOSEC $34 2 payments
  10. XIFAXAN $24 2 payments
  11. Other $113 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

3,947

Median for Emergency Medicine: 88

Drug cost

$29,766

Median for Emergency Medicine: $590

Branded share of claims

19.7%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cefdinir Generic 206 $4,447
Paxlovid Nirmatrelvir/Ritonavir Brand 20 $4,269
Fluconazole Generic 689 $3,600
Albuterol Sulfate Hfa Albuterol Sulfate Brand 210 $3,395
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 369 $3,223
Prednisone Generic 1,116 $2,117
Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort Brand 28 $1,231
Azithromycin Generic 319 $1,125
Cephalexin Generic 187 $789
Mupirocin Generic 101 $691

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$100,913

Of which drugs: $1,143

Medicare patients

1,165

Average age 74

Services billed

5,059

726 women, 439 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 31%
Ischemic heart disease 27%
Chronic kidney disease 22%
Depression 21%
Atrial fibrillation 15%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 24 24 $642
Injection, methylprednisolone acetate, 1 mg J1010 Office 30 2,601 $256
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 31 $18
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 24 96 $7
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 Office 37 39 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $329
$329 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record